Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New COVID-19 drug enters human testing phase

NCT ID NCT07157007

Summary

This study is testing a new oral medication called ratutrelvir, given alongside standard COVID-19 treatment, in adults with mild to moderate symptoms. The main goals are to find a safe and effective dose and to see how well it helps people recover from COVID-19 symptoms. About 90 participants who test positive and have had symptoms for less than 5 days will take the study drug at home.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chang Gung Memorial Hospital, Linkou Branch

    NOT_YET_RECRUITING

    Taoyuan District, Taoyuan, 333, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Chonnam National University Hospital

    NOT_YET_RECRUITING

    Gwangju, Donggu, 61469, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Hallym University Sacred Heart Hospital Gangnam

    NOT_YET_RECRUITING

    Seoul, Seoul, 07441, South Korea

    Contact Email: •••••@•••••

  • Inha University Hospital

    NOT_YET_RECRUITING

    Incheon, Jung-gu, 22332, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Kaohsiung Medical University Hospital

    NOT_YET_RECRUITING

    Kaohsiung City, Kaohsiung, 807, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Key Health

    RECRUITING

    Sydney, New South Wales, 2000, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Momentum Clinical Research Taringa

    RECRUITING

    Brisbane, Queensland, 4068, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novatrial

    RECRUITING

    Charlestown, New South Wales, 2290, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Paratus Clinical(Clinical Trials Institute, Torquay)

    NOT_YET_RECRUITING

    Torquay, Victoria, 3228, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Research Institute of Virology

    RECRUITING

    Tashkent, Tashkent, 100194, Uzbekistan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Taichung Veterans General Hospital

    NOT_YET_RECRUITING

    Taichung, Taichung, 407, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Taipei Medical University Hospital

    NOT_YET_RECRUITING

    Taipei, Taipei, 110, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Taoyuan General Hospital

    NOT_YET_RECRUITING

    Taoyuan District, Taoyuan, 33004, Taiwan

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Catholic University of Korea, Eunpyeong St. Mary's Hospital

    NOT_YET_RECRUITING

    Seoul, Eunpyeong-gu, 07441, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Wonju Severance Christian Hospital

    NOT_YET_RECRUITING

    Wŏnju, Gangwon-do, 26426, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.